Syri Limited Recalls Baclofen 10mg/5ml Oral Solution Due to Crystallisation Concerns
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Syri Limited (T/A SyriMed) is recalling batches of Baclofen 10mg/5ml Oral Solution as a precautionary measure after crystallisation was observed in the medicine.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on April 6, 2026 and geographically references United Kingdom. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, mhra, pharmaceuticals.
What Happened
Syri Limited, trading as SyriMed, has initiated a Class 2 medicines recall for Baclofen 10mg/5ml Oral Solution. This precautionary action follows reports of crystallisation occurring in the oral solution over time.
Which Products Are Affected
The recall involves the following pharmaceutical product:
- Product Name: Baclofen 10mg/5ml Oral Solution
- Manufacturer: Syri Limited, T/A SyriMed
- Recall Reference: EL(26)A/06
- Alert Class: Class 2 Recall
The recall affects specific batches of the product where crystallisation has been observed.
What You Should Do
Healthcare professionals and patients are advised to check their stock for the affected medication. If you have the product, you should follow the guidance provided in the official MHRA alert regarding the quarantine and return of affected batches. For further information, consumers can contact SyriMed or refer to the official government notice.
Why This Matters
Crystallisation in an oral solution can lead to an uneven distribution of the active ingredient, potentially resulting in incorrect dosing or reduced efficacy for the patient.
Source
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this MHRA medicine alert: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,377 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 6, 2026.
Frequently Asked Questions
Common questions about this MHRA medicine alert.